Overview

KPV (Lys-Pro-Val) is the C-terminal active tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH). It retains the anti-inflammatory and cytoprotective properties of full α-MSH but without the pigmentation and melanocortin signaling effects, making it highly targeted for gut and wound healing applications. Research has demonstrated potent anti-inflammatory effects in inflammatory bowel disease models, and the peptide can be effectively delivered orally due to intestinal epithelial uptake via the PepT1 transporter.

Mechanism of Action

KPV exerts anti-inflammatory effects through multiple pathways: binding to melanocortin-1 receptor (MC1R) on immune cells and epithelial cells; inhibiting NF-κB nuclear translocation in macrophages; reducing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β); and directly inhibiting inflammatory signaling in intestinal epithelial cells via PepT1-mediated uptake. The PepT1 transporter enables effective oral delivery to inflamed intestinal tissue.

Potential Benefits

  • Potent anti-inflammatory effects in colitis and IBD models
  • Oral bioavailability via intestinal PepT1 transporter
  • Reduction of TNF-α, IL-6, IL-1β in gut inflammatory models
  • Complement to BPC-157 in GI healing protocols
  • Wound healing acceleration without melanocortin pigmentation effects
  • Cytoprotective effects on intestinal epithelium

Dosage Protocols

The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.

Typical Range100-500 mcg/day
Beginner100-200 mcg/day oral or subcutaneous
Intermediate300-500 mcg/day
Advanced500-1000 mcg/day for inflammatory bowel conditions
Cycle Duration4-8 weeks
Cycle Off4 weeks

Oral KPV is effective for GI inflammation due to local intestinal action. Subcutaneous dosing for systemic anti-inflammatory effects. Lower doses effective for IBD-like conditions; higher doses for acute inflammation management.

Routes of Administration

Oral Moderate

Effective for GI tract inflammation; tripeptide size allows some survival through proteolytic degradation

Subcutaneous Injection High

Systemic anti-inflammatory effects; consistent bioavailability for skin and immune applications

Stacking Protocols

Popular research stacks involving KPV:

IBD and Gut Stack

Intestinal inflammation control, mucosal repair, and antimicrobial protection

All three can be orally administered to target the GI tract; complementary anti-inflammatory and healing mechanisms.

Skin Inflammation Stack

Psoriasis, eczema, and inflammatory skin condition management

KPV reduces NF-κB-driven skin inflammation; GHK-Cu promotes tissue repair and anti-inflammatory collagen remodeling.

Reconstitution

Typical Vial Size5mg, 10mg
BAC Water1-2ml per 5mg vial
StorageRefrigerate at 2-8°C after reconstitution
Shelf Life28-30 days refrigerated

Need exact syringe measurements?

Amino Acid Sequence

Lys-Pro-Val (KPV)

Side Effects & Safety

  • Very well-tolerated in available animal studies
  • Minimal adverse effects reported

Synergistic Compounds

The following compounds have been studied alongside KPV for potential complementary or synergistic effects:

Learn More

References & Further Reading

More Peptides in This Category